



Express Mail Label No.: EV669116818US  
Date of Deposit: May 3, 2005

Attorney Docket No. 350957-0014 RHI-011US

**IN THE UNITED STATES PATENT AND TRADEMARK OFFICE**

APPLICANT: CLOUATRE, Dallas  
TITLE: TREATING CACHEXIA AND EXCESSIVE CATABOLISM  
WITH (-)-HYDROXYCITRIC ACID  
SERIAL NUMBER 10/616,321  
FILING DATE July 7, 2003  
GROUP ART UNIT 1614

Boston, Massachusetts

Commissioner for Patents  
P.O. Box 1450  
Alexandria, Virginia 22313-1450

**TRANSMITTAL LETTER**

Dear Sir:


Transmitted herewith for filing in the above-referenced patent application are the following documents:

- ☒ Supplemental Information Disclosure Statement;
- ☒ PTO Form 1449;
- ☒ Copies of Cited Reference C1; and
- ☒ Return Postcard

If the enclosed papers are considered incomplete, the Mail Room is respectfully requested to contact the undersigned collect at telephone (617) 342-4000. No fees are believed to be due. This paper is submitted in duplicate for the Office's convenience.

Dated: May 3, 2005

Respectfully submitted,

  
James F. Ewing  
Reg. No. 52,875  
Attorney(s) for Applicants  
Customer No.: 48329  
Foley & Lardner, LLP.  
111 Huntington Avenue  
Boston, Massachusetts 02199  
Tel: (617) 342-4000  
Fax: (617) 342-4001



5-4-05

IFW

Express Mail Label No.: EV669116818US  
Date of Deposit: May 3, 2005

Attorney Docket No. 350957-0014 RHI-011US

**IN THE UNITED STATES PATENT AND TRADEMARK OFFICE**

APPLICANT: CLOUATRE, Dallas  
TITLE: TREATING CACHEXIA AND EXCESSIVE CATABOLISM  
WITH (-)-HYDROXYCITRIC ACID  
SERIAL NUMBER 10/616,321  
FILING DATE July 7, 2003  
GROUP ART UNIT 1614

Boston, Massachusetts

Commissioner for Patents  
P.O. Box 1450  
Alexandria, Virginia 22313-1450

**SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT**

Dear Sir:

Pursuant to the duty of disclosure under 37 C.F.R. §§1.56, 1.97 and 1.98, Applicants hereby make of record the documents listed below and on the attached modified Form PTO-1449 (submitted in duplicate) in the above-identified application, copies of which are submitted herewith. The order of presentation of the references should not be construed as an indication of the importance of the references.

This Information Disclosure Statement is being been filed:

- ☐ within three months of the filing date of the National Application;  
☒ prior to receipt of first office action on the merits; or  
☐ within three months of receipt of art cited in a related foreign application.

Accordingly, no fee or certification is required. 37 C.F.R. §1.97.

A copy of each of the above-identified information is enclosed unless otherwise indicated on the attached Form PTO-1449 (modified). Copies of US patents and patent publications are not enclosed. It is respectfully requested that the Examiner consider completely the cited information, along with any other information, in reaching a

**FIRST-NAMED INVENTOR: Clouatre**  
**Information Disclosure Statement**


determination concerning the patentability of the present claims, and signs the enclosed form PTO-1449 to evidence that the cited information has been fully considered by the Patent and Trademark Office during the examination of this application.

By submitting this Supplemental Information Disclosure Statement, the Applicant makes no representation that: (1) a search has been performed, of the extent of any search performed, or that more relevant information does not exist; (2) the information cited in the Statement is, or is considered to be, material to patentability as defined in 37 C.F.R. §1.56(b); and (3) the information cited in the Statement is, or is considered to be, in fact, prior art as defined by 35 U.S.C. §102.

Notwithstanding any statements by the Applicant, the Examiner is urged to form his/her own conclusion regarding the relevance of the cited information. An early and favorable action is hereby requested. Please charge any additional fees that may be due, or credit any overpayment of same, to Deposit Account No. 50-3431, Reference No. 350957-0014.

Dated: May 3, 2005

Respectfully submitted,

  
James F. Ewing  
Reg. No. 52,875  
Attorney(s) for Applicants  
Customer No.: 48329  
Foley & Lardner, LLP.  
111 Huntington Avenue  
Boston, Massachusetts 02199  
Tel: (617) 342-4000  
Fax: (617) 342-4001

#158270v1



SPTO Form 1449 Patent and Trademark Office		U.S. Department of Commerce		Attorney Docket No. 351044-0014		Serial No. 10/616,321		
INFORMATION DISCLOSURE STATEMENT				Applicant(s): Clouatre				
				Filing Date: July 7, 2003		Group: 1614		
U.S. PATENT DOCUMENTS								
Examiner Initial		Patent No.	Date	Name	Class	Subclass	Filing Date (if appropriate)	
	A1	5,086,057	04 February 1992	Sasagawa	A01N	43/54	25 April 1991	
FOREIGN PATENT DOCUMENTS								
Examiner Initial		Document No.	Publication Date	Country	Class	Subclass	Translation	
							YES	NO
OTHER DOCUMENTS (including Author, Title, Date, Pertinent Pages, etc.)								
	C1	International Search Report for PCT/US04/21542						
EXAMINER					DATE CONSIDERED			
<small>*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to Applicant. **Copies of references not provided at the time of this submission.</small>								